Ford Brewer
Ford Brewer is a health commentator and researcher focusing on cardiovascular health. He produces content examining topics such as atherosclerosis, arterial plaque, and the physiological effects of compounds like taurine. His published academic research addresses early multidrug treatment strategies for high-risk ambulatory SARS-CoV-2 (COVID-19) infections.
36 claims checked on air: 4 context 1 contradicted 1 overstated 26 supported 4 unverified
What they said on air - supported
Taurine is one of the most abundant free amino acids in human heart muscle.
"Taurine is one of the most abundant free amino acids in human heart muscle." (said at 0:01:33)
Biochemical analyses of human myocardial tissue consistently show that taurine is one of the most abundant intracellular free amino acids in the human heart, reaching tissue concentrations around 10 to 20 mM (approximately 100 times higher than plasma levels), along with glutamine and glutamate.
- supports: The importance of myocardial amino acids during ischemia and reperfusion in dilated left v… (Molecular and cellular biochemistry 2009) · cited 33x in the literature
"Taurine, glutamine, glutamate, aspartate, and alanine are the most abundant intracellular free amino acids in human heart." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Taurine deficiency associated with dilated cardiomyopathy and aging. (Journal of pharmacological sciences 2024) · cited 19x in the literature
"Taurine (2-aminoethanesulfonic acid) is a free amino acid found ubiquitously and abundantly in mammalian tissues. Taurine content in the heart is approximately 20 mM, which is approximately 100 times higher than plasma concentration." (abstract, introduction)
pubmedfull study (doi) - supports: Effect of ischaemia and reperfusion on the intracellular concentration of taurine and glut… (Biochimica et biophysica acta 1997) · cited 50x in the literature
"Taurine and glutamine are the most abundant intracellular free amino acids in mammalian hearts where changes in their intracellular concentrations are likely to influence a number of cellular activities." (abstract, introduction, passage verified)
pubmedfull study (doi)
Taurine is concentrated in the brain, retina, kidneys, and immune cells.
"It's also concentrated in your brain, the retina of your eye, the back of your eye, your kidneys, and your immune cells." (said at 0:01:42)
Extensive biochemical and physiological research establishes that taurine is present at high intracellular concentrations throughout mammalian and human tissues, specifically concentrating in the brain, retina, kidneys, and immune cells (leukocytes, such as neutrophils). In these tissues, taurine functions as a major osmolyte, antioxidant, and cytoprotectant, reaching concentrations of 10 to 70 mmol/kg in tissues such as the brain and retina and up to 50 mM in leukocytes.
- supports: Taurine: new implications for an old amino acid. (FEMS microbiology letters 2003) · cited 430x in the literature
"In mammalian tissues, taurine is ubiquitous and is the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes. In fact, taurine reaches up to 50 mM concentration in leukocytes." (abstract, passage verified)
pubmedfull study (doi) - supports: Phenotype of the taurine transporter knockout mouse. (Methods in enzymology 2007) · cited 155x in the literature
"Taurine, which is the most abundant amino acid in many tissues, is normally found in intracellular concentrations of 10 to 70 mmol/kg in mammalian heart, brain, skeletal muscle, liver, and retina" (abstract, passage verified)
pubmedfull study (doi)
The liver conjugates taurine with bile acids to form bile salts, which assist in eliminating cholesterol through the gut.
"Your liver hooks taurine into bile acids to make bile salts. And bile salts are one of the routes your body uses to move cholesterol out through the gut." (said at 0:02:01)
Hepatic synthesis and conjugation of bile acids is a well-established physiological pathway for cholesterol elimination. In hepatocytes, cholesterol is converted into primary bile acids (such as cholic acid and chenodeoxycholic acid), which are then conjugated with amino acids—predominantly glycine and taurine—to form bile salts prior to biliary secretion into the intestine. A portion of these bile salts and bile-solubilized cholesterol escapes enterohepatic recirculation and is excreted in the feces, serving as a primary route for eliminating cholesterol from the body.
- supports: Biosynthesis of bile acids in mammalian liver. (European journal of drug metabolism and pharmacokinetics 2006) · cited 35x in the literature
"Bile acids are biosynthesized from cholesterol in hepatocytes... Prior to being exported from the liver, bile acids are conjugated with glycine and taurine to produce the bile salts. After excretion into the intestinal tract, primary bile acids are partly converted to secondary bile acids, deoxycholic and lithocholic acids, by intestinal microorganisms." (abstract)
pubmedfull study (doi) - supports: Role of taurine in the pathogenesis of obesity. (Molecular nutrition & food research 2015) · cited 172x in the literature
"Taurine is involved in a diverse array of biological and physiological functions, including bile salt conjugation, osmoregulation, membrane stabilization, calcium modulation, anti-oxidation, and immunomodulation." (abstract, passage verified)
pubmedfull study (doi)
Taurine is involved in cellular calcium regulation, including in arterial wall muscle cells and blood platelets.
"It's involved in how cells handle calcium. Taurine is, including the muscle cells in your artery walls and the platelets floating in your blood." (said at 0:02:04)
Published experimental and mechanistic studies confirm that taurine modulates cellular calcium handling across multiple tissue and cell types, specifically including vascular smooth muscle cells (in arterial walls) and blood platelets. In platelets, taurine modulates agonist-induced intracellular calcium fluxes (delta Ca2+) and suppresses hyperreactivity/aggregation. In arterial smooth muscle cells, taurine regulates extracellular calcium influx and intracellular calcium mobilization, counteracting exaggerated contractile responses and pathological calcium signaling.
- supports: Modulation of receptor-dependent increase of calcium ions in human platelets by taurine. (Arzneimittel-Forschung 1992) · cited 8x in the literature
"In the present experiments human platelet calcium responses to PAF were measured by a fluorescent label "Quin-2" method. Preincubation with 0.01 mol/l of taurine decreased effects of PAF by 250 nmol/l if the initial Ca intracellular response (delta Ca2+) to inductor was more than 400 nmol/l... Hence, some effects of taurine may be ascribed to its modulating influence on secondary Ca2+ messenger." (abstract, results, passage verified)
pubmed - supports: Effects of taurine on the reactivity of aortas from diabetic rats. (Life sciences 2008) · cited 39x in the literature
"Incubation of endothelium-denuded aortic rings with 10 mM, but not 5 mM, taurine for 2 h reduced the augmented contractile responses of the tissues from diabetic rats to norepinephrine close to control levels, and this was associated with inhibition of responses linked to the release and influx of calcium, and protein kinase C activation." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Complementary vascular-protective actions of magnesium and taurine: a rationale for magnes… (Medical hypotheses 1996) · cited 38x in the literature
"Although the amino acid taurine can increase systolic calcium transients in cardiac cells (and thus has positive inotropic activity), it has other actions which tend to reduce [Ca2+]i. Indeed, in animal or clinical studies, taurine lowers elevated blood pressure, retards cholesterol-induced atherogenesis, prevents arrhythmias and stabilizes platelets--effects parallel to those of magnesium." (abstract, passage verified)
pubmedfull study (doi)
Taurine plays a functional role in cellular mitochondrial function and energy production.
"And taurine also shows up in mitochondrial function. Mitochondria, remember, the powerhouses of the cell. That's the energy machinery." (said at 0:02:24)
Published biochemical and physiological literature confirms that taurine plays an established functional role in mitochondrial activity and cellular energy metabolism. Intracellular taurine is required for proper mitochondrial protein synthesis (including the taurine modification of mitochondrial tRNAs), maintenance of respiratory chain complex I activity, oxygen consumption, and ATP generation.
- supports: Differences Between Physiological and Pharmacological Actions of Taurine. (Advances in experimental medicine and biology 2022) · cited 32x in the literature
"Both pharmacological and physiological taurine increased contractile function and oxygen consumption... ATP generation from available substrates, glucose, fatty acids, and acetate was increased for both the physiological and pharmacological actions of taurine. However, taurine supplementation enhanced ATP generation by elevating respiratory chain complex I activity and by stimulating metabolic flux through reductions in the NADH/NAD + ratio" (abstract, results)
pubmedfull study (doi) - supports: Taurine and Metabolic Disorders: From Mechanisms to Clinical Implications. (Annals of nutrition & metabolism 2026)
"Unlike proteinogenic amino acids, taurine exerts diverse physiological functions, including bile acid conjugation, osmoregulation, antioxidant defense, and mitochondrial support. Emerging evidence indicates that taurine modulates key metabolic processes implicated in obesity, type 2 diabetes, metabolic dysfunction-associated liver disease, and metabolic syndrome. Mechanistically, taurine influences insulin signaling, lipid oxidation, inflammatory cascades (e.g., nuclear factor-kappa B), and energy metabolism via pathways involving AMP-activated protein kinase, peroxisome proliferator-activated receptor alpha, and mitochondrial function." (abstract, background, passage verified)
pubmedfull study (doi)
In rabbits fed a 2% cholesterol diet for 14 weeks, roughly 72% of the thoracic aorta was covered in lesions, which was reduced to 58% at a lower taurine dose and 52% at a higher taurine dose in drinking water.
"Rabbits on a 2% cholesterol diet for 14 weeks ended up with roughly 72% of the thoracic aorta covered in the lesion... Add taurine to the drinking water and that came down to 58% at the lower dose and 52% at the higher dose." (said at 0:03:34)
A 1990 animal study evaluated the effect of taurine in rabbits fed a 2% cholesterol diet for 14 weeks. Control animals developed atherosclerotic lesions covering 72.4 ± 19% of the thoracic aorta, whereas the addition of taurine to drinking water at 0.2% and 0.5% significantly reduced lesion coverage to 58 ± 15% and 52.5 ± 12%, respectively. Because this evidence is derived entirely from an animal model, the certainty of the evidence is very low.
In rabbits fed a 2% cholesterol diet, taurine supplementation reduced aortic lesion size without significantly affecting serum or tissue cholesterol levels.
"Taurine had no significant effect on serum or tissue cholesterol in those animals. The lesion in the wall shrank, the artery wall shrank, and the cholesterol in the blood stayed right where it had been from the very beginning." (said at 0:04:30)
Animal experimental data directly match the claim. In a study of rabbits maintained on a 2% cholesterol diet for 14 weeks, taurine supplementation (0.2% and 0.5% in drinking water) significantly reduced the percentage of thoracic aorta area covered by atherosclerotic lesions compared to controls, while exerting no significant effect on serum or tissue cholesterol concentrations. Because this evidence is limited to animal models, the certainty for human health outcomes is very low.
Watanabe heritable hyperlipidemic rabbits have a genetic LDL receptor defect causing spontaneous arterial disease development without a high-fat diet.
"So the Watanabe rabbit is bred with a defect in the LDL receptor. So it builds arterial disease on its own without anybody feeding it any kind of special diet." (said at 0:05:20)
The Watanabe heritable hyperlipidemic (WHHL) rabbit is a well-established animal model of human familial hypercholesterolemia. It possesses a genetic defect causing functional deficiency of the low-density lipoprotein (LDL) receptor, which leads to severe hypercholesterolemia and spontaneous arterial atherosclerosis on standard laboratory chow without the need for dietary cholesterol or high-fat supplementation.
Administering taurine in drinking water to Watanabe rabbits for 24 weeks decreased aortic plaque lesions by approximately 31%.
"You put taurine in the drinking water of a Watanabe rabbit for 24 weeks and the lesions, the plaque, starts decreasing. It decreased about 31% after 24 weeks." (said at 0:05:40)
A 2002 animal study evaluated the effects of taurine in Watanabe heritable hyperlipidemic (WHHL) rabbits. Administering 0.3% taurine in drinking tap water for 24 weeks decreased aortic lesions by 31% (measured as intimal thickening) and reduced cholesteryl ester accumulation and lipid peroxidation markers. Because this evidence is derived entirely from an animal model, the certainty of evidence for human cardiovascular outcomes is very low.
In Watanabe rabbits given taurine, cholesterol ester content dropped by 35% in the aortic arch, 43% in the thoracic aorta, and 44% in the abdominal aorta, with fewer macrophages in the artery wall.
"cholesterol ester content in the aortic arch, the thoracic aorta, and the abdominal aorta dropped by 35, 43, and 44%. There were fewer macrophages and again, macrophages. There were fewer immune cells sitting in the wall." (said at 0:06:10)
A 2002 study in Watanabe heritable hyperlipidemic (WHHL) rabbits found that taurine supplementation (0.3% in drinking water for 24 weeks) significantly reduced cholesteryl ester content in the aortic arch by 35%, in the thoracic aorta by 43%, and in the abdominal aorta by 54% (the speaker stated 44% for the abdominal aorta). Immunohistochemical analysis confirmed a decrease in macrophages within the aortic intima. Because this evidence comes exclusively from an animal model, the certainty of evidence is graded as very low.
- supports: Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WH… (Atherosclerosis 2002) · cited 72x in the literature
"Taurine significantly decreased cholesteryl ester content of aortic arch, thoracic aorta, and abdominal aorta by 35, 43, and 54%, respectively. Concomitantly, activity of acyl-CoA:cholesterol acyltransferase (ACAT), an enzyme responsible for cholesterol esterification, was also significantly decreased. Immunohistochemical analysis revealed decreased macrophages in the intima of taurine-treated rabbits." (abstract, results, passage verified)
pubmedfull study (doi)
In taurine-treated Watanabe rabbits, blood pressure and serum cholesterol remained unchanged despite reductions in arterial plaque.
"So what about blood pressure? That was not changed. Cholesterol in the blood, serum cholesterol, that was not changed." (said at 0:07:05)
In an animal study evaluating the anti-atherosclerotic effects of taurine in Watanabe heritable hyperlipidemic (WHHL) rabbits, taurine supplementation significantly reduced aortic intimal thickening and cholesteryl ester content without altering blood pressure or serum cholesterol concentrations. Because the evidence is derived exclusively from an animal model, the certainty of evidence is graded as very low.
No clinical trial has ever imaged human arterial plaque in response to taurine supplementation.
"Nobody's ever imaged human plaque in a taurine trial." (said at 0:10:48)
A systematic search of published clinical literature confirms that no human clinical trial has ever evaluated or imaged human arterial plaque (such as via carotid ultrasound, coronary CTA, or intravascular imaging) in response to taurine supplementation. While clinical trials of taurine in humans have assessed functional vascular parameters such as carotid-femoral pulse wave velocity (cfPWV, a measure of arterial stiffness; e.g., PMID 27163699) or endothelial function, and systematic reviews note that large-scale clinical trials verifying taurine's cardiovascular efficacy remain lacking (PMID 41475256), no plaque imaging trial exists in humans.
- context: Taurine supplementation attenuates delayed increase in exercise-induced arterial stiffness… (Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 2016) · cited 30x in the literature
"On the morning of exercise and for 4 days thereafter, we measured serum malondialdehyde (MDA) and carotid-femoral pulse wave velocity (cfPWV) as indices of oxidative stress and arterial stiffness, respectively." (abstract, methods, passage verified)
pubmedfull study (doi) - supports: Taurine as a functional ingredient: Dietary sources, non-thermal extraction technologies, … (Food chemistry 2026) · cited 5x in the literature
"Addressing these issues through optimized extraction, targeted product innovation, and well-designed, large scale clinical trial to confirm efficacy, optimize dosing, and identify populations most likely to benefit represents a key pathway for expanding its functional food applications." (abstract, conclusions, passage verified)
pubmedfull study (doi)
In the 12-week trial of taurine in diabetic patients, approximately 66 of 80 patients on taurine completed the trial with complete data, whereas nearly all placebo patients finished.
"About 66 of 80 made it through with complete data on taurine. In other words, people were dropping out and not at the same rate whether they're placebo or taurine. Nearly everybody on the placebo trial finished, and what, 2/3, 3/4 of the taurine people finished." (said at 0:13:23)
A 12-week randomized, double-blind, placebo-controlled clinical trial evaluated taurine supplementation (2.4 g/day) in patients with type 2 diabetes, enrolling approximately 80 patients per arm (82 in the taurine group and 83 in the placebo group). The speaker's description of the study design, sample size (~80 per group), 12-week duration, and completion patterns matches the published trial.
A clinical trial in 120 individuals with prehypertension taking 1.6 g/day of taurine showed a systolic blood pressure reduction of 7.2 mmHg compared to 2.6 mmHg for placebo.
"There's an earlier trial that points the same direction, though, in 120 people with prehypertension, early high blood pressure, on 1.6 grams a day, and systolic blood pressure came down 7.2 against 2.6." (said at 0:13:52)
A 12-week randomized, double-blind, placebo-controlled trial in 120 prehypertensive individuals (Sun et al., 2016) evaluated 1.6 g/day of taurine supplementation against placebo. The study reported that mean clinic systolic blood pressure fell by 7.2 mmHg in the taurine group compared to 2.6 mmHg in the placebo group (and diastolic blood pressure fell by 4.7 mmHg vs. 1.3 mmHg), exactly matching the figures in the claim.
Coronary artery calcium scores reflect only hardened, calcified plaque and do not detect soft arterial plaque.
"And the plaque on a calcium score, that's only the stable plaque. Calcium scores don't show you soft plaque. It only shows material that's been sitting around long enough to harden and stabilize." (said at 0:18:03)
Coronary artery calcium (CAC) scoring evaluates calcified (hardened) atherosclerotic plaque on non-contrast CT imaging and does not visualize non-calcified (soft) plaque. Detection and quantification of non-calcified soft plaque, fibrofatty components, or necrotic core require contrast-enhanced coronary CT angiography (CCTA). Consequently, individuals can present with a calcium score of zero while still harboring non-calcified plaque.
Carotid intima-media thickness (CIMT) ultrasound imaging is able to detect soft, non-calcified plaque in the carotid artery wall.
"With a CIMT, you can read the calcification. The wall of the carotid artery picks up the soft plaque while it's still soft." (said at 0:18:03)
Carotid ultrasound imaging (including protocols assessing carotid intima-media thickness and plaque morphology) uses B-mode high-resolution ultrasound to evaluate the arterial wall and characterize plaque composition. On B-mode ultrasound, non-calcified, lipid-rich, or vulnerable "soft" plaques appear hypoechoic or echolucent, whereas calcified and fibrous plaques appear hyperechoic/echogenic with acoustic shadowing. Clinical studies and surgical trials (such as the ACST-1 trial) routinely use ultrasound to identify and grade soft/echolucent plaques versus calcified structures.
- supports: Plaque Echolucency and the Risk of Ischaemic Stroke in Patients with Asymptomatic Carotid … (European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2016) · cited 49x in the literature
"On ultrasound, potentially "high risk" carotid plaques may appear echolucent. In this study, whether a confident classification of echolucent plaque was a predictor of future ipsilateral ischaemic stroke in asymptomatic patients randomized to medical therapy in the Asymptomatic Carotid Surgery Trial-1 (ACST-1) was assessed. We performed a post-hoc analysis of 814 ACST-1 patients randomized to medical therapy alone with baseline plaque assessment classified as definitely echolucent (> 25% soft plaque) or nonecholucent (< 25% soft plaque)." (abstract, methods, passage verified)
pubmedfull study (doi) - supports: Role of carotid plaque analysis in therapeutic decision-making for carotid disease. (International angiology : a journal of the International Union of Angiology 2025) · cited 1x in the literature
"Recently, specific features of the atherosclerotic plaque have attracted increasing attention; for example, total plaque area, juxtaluminal black area, intraplaque hemorrhage, and mainly echolucent plaques are associated with high risk of late stroke, and these features now influence the therapeutic choices." (abstract, background, passage verified)
pubmedfull study (doi)
In human trials, taurine doses typically range from 1.5 to 3 grams per day for 8 to 12 weeks.
"So the doses studied run mostly 1 and a half to three grams a day for 8 to 12 weeks." (said at 0:19:00)
Systematic reviews and meta-analyses of randomized clinical trials evaluating oral taurine supplementation indicate that intervention doses typically span 1 to 3 g/day (within broader trial ranges of 0.5 to 6 g/day) and commonly run for durations of 8 to 12 weeks (ranging from acute exposures to several months).
An echocardiogram does not effectively visualize arterial plaque.
"Will an echo show an arterial plaque? Not really." (said at 0:30:45)
Standard transthoracic echocardiography evaluates cardiac chamber structure, valvular function, hemodynamics, and regional wall motion abnormalities, but it does not directly visualize atherosclerotic plaque in the coronary arteries. Direct visualization and characterization of coronary arterial plaque require specialized imaging modalities such as coronary computed tomography angiography (CCTA), intravascular ultrasound (IVUS), or optical coherence tomography. Echocardiography is limited to detecting functional downstream consequences (such as wall motion abnormalities or diastolic dysfunction) or surrogate anatomical markers (such as epicardial adipose tissue thickness).
Nattokinase decreases blood clot formation and the strength of clots rather than decreasing plaque stability.
"Nattokinase clearly appears to be decreasing the clot formation or the strength of clots, which is different from decreasing the stability of a plaque." (said at 0:36:50)
Clinical trial evidence demonstrates that nattokinase enhances systemic fibrinolysis and anticoagulation—decreasing clot formation and accelerating clot degradation—without destabilizing vascular plaques or increasing plaque vulnerability. Randomized trials and clinical cohort studies confirm that nattokinase promotes antithrombotic and fibrinolytic activity (increasing D-dimer and APTT while decreasing Factor VIII activity) while either having no effect on or actually reducing carotid intima-media thickness and plaque size rather than causing plaque rupture or reducing plaque stability.
Isometric grip strength exercises help lower blood pressure.
"Get a squeeze thing to do some isometrics with that, a grip strength, and do that and that'll help your blood pressure, too." (said at 0:47:15)
Multiple systematic reviews and meta-analyses of randomized controlled trials confirm that regular isometric handgrip training significantly reduces resting blood pressure. In individuals with hypertension, isometric handgrip training (typically performed as repeated 2-minute contractions several times per week over 8 or more weeks) leads to clinically meaningful reductions in resting systolic blood pressure (approximately 5 to 8 mmHg) and diastolic blood pressure (approximately 2 to 5 mmHg).
Most forms of heart failure respond positively to high-intensity exercise training.
"Another place that actually responds positively, it's sort of more structural, is most heart failure. People think, 'Oh, if you've got heart failure, you shouldn't stress the heart.' Actually, the opposite. You should do intensity with the heart. It responds well to that." (said at 0:52:00)
Multiple systematic reviews and meta-analyses of randomized controlled trials demonstrate that patients across major heart failure phenotypes (including heart failure with reduced ejection fraction [HFrEF] and preserved ejection fraction [HFpEF]) respond positively to high-intensity interval training (HIIT). HIIT consistently improves cardiorespiratory fitness (peak VO2), cardiac function (left ventricular ejection fraction), functional capacity (6-minute walk test distance), and health-related quality of life, frequently showing equal or superior gains compared to moderate-intensity continuous training or standard care.
- supports: Physiological and psychological outcomes of high intensity interval training in patients w… (Heart & lung : the journal of critical care 2024) · cited 6x in the literature
"HIIT improves VO 2peak , LVEF and HRQoL in patients with heart failure, the improvements seen in VO 2peak and LVEF are superior in HIIT compared to MCT and UC." (abstract, conclusions)
pubmedfull study (doi) - supports: High-intensity Interval Versus Moderate-intensity Continuous Training in Heart Failure Reh… (Heart international 2025)
"HIIT appears to be more effective than MICT in improving functional capacity, such as LVEF, peak VO 2 and 6MWT, as well as cardiac functional outcome." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Effect of high-intensity interval training versus moderate intensity continuous training i… (Respiratory medicine 2026) · cited 2x in the literature
"This systematic review demonstrates that HIIT is superior to MICT in an overall context of HFrEF and HFpEF collectively." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Hemoglobin A1C testing misses more than half of prediabetes and diabetes cases.
"A1C misses over half of pre-diabetes and diabetes." (said at 1:00:45)
Systematic reviews and meta-analyses evaluating the diagnostic accuracy of HbA1c against oral glucose tolerance tests (OGTT) confirm that standard HbA1c screening has a pooled sensitivity of approximately 49% to 50% for identifying prediabetes and previously undiagnosed type 2 diabetes. Consequently, screening with HbA1c alone fails to identify roughly half to slightly more than half of individuals who meet the diagnostic criteria for dysglycemia on standard glucose tolerance testing.
- supports: Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: … (BMJ (Clinical research ed.) 2017) · cited 330x in the literature
"HbA 1c had a mean sensitivity of 0.49 (95% confidence interval 0.40 to 0.58) and specificity of 0.79 (0.73 to 0.84), for identification of pre-diabetes, though different studies used different cut-off values." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Diagnostic accuracy of tests for type 2 diabetes and prediabetes: A systematic review and … (PloS one 2020) · cited 94x in the literature
"The pooled sensitivity, specificity, positive (LR+) and negative likelihood ratio (LR-) for diagnosing diabetes with HbA1c (6.5%; venous sample; n = 17 studies) were 50% (95% CI: 42-59%), 97.3% (95% CI: 95.3-98.4), 18.32 (95% CI: 11.06-30.53) and 0.51 (95% CI: 0.43-0.60), respectively." (abstract, results, passage verified)
pubmedfull study (doi)
Fasting glucose testing misses more than half of prediabetes and diabetes cases.
"Fasting glucose misses over half of pre-diabetes and diabetes." (said at 1:00:50)
The claim is supported by systematic reviews and diagnostic accuracy studies evaluating fasting plasma glucose (FPG) against the 2-hour oral glucose tolerance test (OGTT). A comprehensive systematic review and meta-analysis published in the BMJ found that FPG had a pooled sensitivity of only 25% (95% CI: 19% to 32%) for identifying prediabetes, meaning it misses approximately 75% of prediabetes cases defined by OGTT. Similarly, for diabetes screening, FPG at the standard threshold misses roughly 50% or more of individuals who have diabetic-range dysglycemia detected exclusively on a 2-hour post-load glucose test.
American Diabetes Association publications acknowledge that hemoglobin A1C and fasting glucose miss over half of prediabetes and diabetes cases.
"The ADA, American Diabetes Association, which recommends using A1C and fasting glucose, acknowledges in their own research, their own journals, that these two things miss over half of pre-diabetes and diabetes." (said at 1:01:12)
Publications in the American Diabetes Association journal Diabetes Care confirm that fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) have poor diagnostic sensitivity when compared against oral glucose tolerance tests (OGTT), failing to identify a substantial fraction—in some populations more than half—of individuals with prediabetes or abnormal glucose tolerance. For example, a study published in Diabetes Care (PMID: 25338926) evaluated screening accuracy for abnormal glucose tolerance (2-hour OGTT glucose ≥7.8 mmol/L) and demonstrated a sensitivity of only 32% for FPG alone and 53% for HbA1c alone. Even when combining FPG and HbA1c, sensitivity reached only 64% (missing 36% of cases). Similarly, another study in Diabetes Care (PMID: 22912427) noted that HbA1c identified a smaller proportion of prediabetic individuals (38% vs 42%) and type 2 diabetes individuals (11% vs 15%) than OGTT, with a concordance rate of only 54% for prediabetes and 44% for diabetes, confirming that conventional fasting glucose and HbA1c tests fail to detect many cases.
- supports: Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral gluc… (Diabetes care 2012) · cited 36x in the literature
"OGTT results showed 42% of the subjects had prediabetes and 15% had type 2 diabetes mellitus (T2DM), whereas the corresponding figures based on HbA(1c) were 38 and 11%, with a respective concordance rate of 54 and 44%." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Detection of abnormal glucose tolerance in Africans is improved by combining A1C with fast… (Diabetes care 2015) · cited 45x in the literature
"When determining abnormal glucose tolerance from the OGTT (2-h glucose ≥7.8 mmol/L), sensitivities of FPG for the total, normal, and variant hemoglobin groups were 32%, 32%, and 33%, respectively. Sensitivities for A1C were 53%, 54%, and 47%. For FPG and A1C combined, sensitivities were 64%, 63%, and 67%." (abstract, results)
pubmedfull study (doi)
Glucose challenge testing without measuring an insulin response misses approximately 20% of metabolic disease cases.
"Really, you still tend to miss about 20% of metabolic disease if you're not getting an insulin response as well. It's the Kraft insulin survey if you've never heard of that." (said at 1:01:47)
The speaker's reference to the Kraft dataset accurately reflects published findings on oral glucose tolerance testing combined with insulin assays. In retrospective analyses of Dr. Joseph Kraft's historical database of several thousand patients undergoing oral glucose tolerance testing with concurrent insulin measurements, standard glucose clearance testing alone failed to identify metabolic dysfunction in a substantial subset of patients. Specifically, among patients with normal glucose tolerance (representing 54% of the cohort), approximately 50% (amounting to ~27% of the entire cohort) exhibited delayed or excessive dynamic hyperinsulinemia (often termed occult diabetes or early metabolic disease) despite normal blood glucose clearance. Evidence is observational and cross-sectional.
Aging causes a substantial loss of the connective tissue protein elastin throughout the entire body.
"When you get old, things happen, like the connective tissue loses a lot of spring. Elastin is the protein; you lose a lot of it, not just in your skin, all over your body." (said at 1:05:56)
Elastin is an extracellular matrix protein essential for the elasticity and biomechanical function of connective tissues throughout the body, including the skin, arteries, and lungs. Elastic fibers are primarily synthesized during early development and undergo minimal regeneration in adulthood. As a result, physiological aging leads to the progressive degradation, fragmentation, and net loss of functional elastic fibers across multiple organ systems.
Fact-checked episodes
Publications